Flexus Biosciences, Inc.

Bristol-myers Squibb Compnay

Leland Stanford Junior University

Flx Bio, Inc.

Rapt Therapeutics, Inc.

Siteone Therapeutics, Inc.

James Ross Walker

Jay Patrick Powers

Hunter Paul Shunatona

Mikhail Zibinsky

Maureen Kay Reilly

Hilary Plake Beck

Maksim Osipov

Juan Carlos Jaen

James Aaron Balog

David K Williams

Weifang Shan

Audris Huang

Jay A Markwalder

Emily Charlotte Cherney

Weiwei Guo

Ian Scott Young

David Juergen Wustrow

John Michael Ketcham

Jeffrey J Jackson

Ashkaan Younai

Omar Robles-Resendiz

Dennis X Hu

Berenger Biannic

Minna Hue Thanh Bui

Benjamin Cohen

Steven P Seitz

Petinka I Vlahova

Jennifer Leigh Nelson

Liping Zhang

Gregory L Beutner

Michael S Bultman

Yu Fan

Sergei Kolotuchin

Francisco Gonzalez-Bobes

Kenneth Joseph Fraunhoffer

Adam Joseph Freitag

Tamar Rosenbaum

Albert J Delmonte

Prantik Maity

George P Miljanich

Jeffrey E Merit

Justin Du Bois

John Mulcahy

Sherwood I Parker

Hassan Pajouhesh

Matthew Axtman

Bernard H Hyams

Stephen Shapiro

Jeffrey James Jackson

The present disclosure relates to amorphous and crystalline forms of (R)—N-(4-chlorophenyl)-2-(1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide and its salts and hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.

Amorphous and crystalline forms of IDO inhibitors

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Immunoregulatory agents

The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.

Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation

The present disclosure relates to amorphous and crystalline forms of (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoro-quinolin-4-yl) cyclohexyl)propanamide and its salts and hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.

Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.

Chemokine receptor modulators and uses thereof

Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.

Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function, for example conditions associated with pain. The compounds are 10',11&#x2032;-modified saxitoxins. The compounds are optionally additionally modified at carbon 13. In certain embodiments, the 10&#x2032;,11&#x2032;-modified saxitoxins are of Formula I: where R, Rand Rare as described herein. Also provided herein are methods of treating pain in a mammal comprising administering an effective treatment amount of a 10&#x2032;,11&#x2032; modified saxitoxin or composition to a mammal. In an embodiment, the mammal is a human. 

10',11&#x2032;-modified saxitoxins useful for the treatment of pain

Growing community of inventors

Verona, WI, United States of America

James Ross Walker